

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <b>CONCANNON BRIAN</b>			2. Issuer Name and Ticker or Trading Symbol <b>HAEMONETICS CORP [ HAE ]</b>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <b>President &amp; CEO</b>		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <b>08/01/2013</b>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
<b>400 WOOD ROAD</b>			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street) <b>BRAINTREE MA 02184</b>								
(City) (State) (Zip)								

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/01/2013		M		3,000 <sup>(1)</sup>	A	\$13.0525	118,798 <sup>(2)</sup>	D	
Common Stock	08/01/2013		S		3,000 <sup>(1)</sup>	D	\$42.3	115,798 <sup>(2)</sup>	D	
Common Stock	08/01/2013		M		10,000 <sup>(1)</sup>	A	\$11.3175	125,798 <sup>(2)</sup>	D	
Common Stock	08/01/2013		S		10,000 <sup>(1)</sup>	D	\$42.2244	115,798 <sup>(2)</sup>	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non-Qualified Stock Option (right to buy)	\$11.3175	08/01/2013		M			10,000	09/15/2004 <sup>(3)</sup>	09/15/2013	Common Stock	10,000	\$42.23	10,000	D	
Non-Qualified Stock Option (right to buy)	\$13.0525	08/01/2013		M			3,000	05/05/2005 <sup>(3)</sup>	05/05/2014	Common Stock	3,000	\$42.3	18,000	D	
Non-Qualified Stock Option (right to buy)	\$25.535							10/24/2008 <sup>(3)</sup>	10/24/2014	Common Stock	45,780		45,780	D	
Non-Qualified Stock Option (right to buy)	\$26.47							10/27/2010 <sup>(3)</sup>	10/27/2016	Common Stock	159,350		159,350	D	
Non-Qualified Stock Option (right to buy)	\$27.275							10/22/2009 <sup>(3)</sup>	10/22/2015	Common Stock	57,176		57,176	D	
Non-Qualified Stock Option (right to buy)	\$27.495							10/27/2011 <sup>(3)</sup>	10/27/2017	Common Stock	236,750		236,750	D	
Non-Qualified Stock Option (right to buy)	\$27.685							04/02/2010 <sup>(3)</sup>	04/02/2016	Common Stock	65,690		65,690	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non-Qualified Stock Option (right to buy)	\$30.67							10/25/2012 <sup>(3)</sup>	10/25/2018	Common Stock	219,572		219,572	D	
Non-Qualified Stock Option (right to buy)	\$39.055							10/24/2013 <sup>(3)</sup>	10/24/2019	Common Stock	250,382		250,382	D	
Performance Shares	\$0.0							03/31/2017 <sup>(4)</sup>	12/31/2017 <sup>(4)</sup>	Common Stock	50,000		50,000	D	

**Explanation of Responses:**

- Pursuant to a 10b5-1 Plan.
- Total includes Restricted Stock Awards and/or Restricted Stock Units that are subject to restrictions until vesting requirements are met. Grant was made under 2005 Long Term Incentive Compensation Plan.
- Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.
- Market Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Market Stock Unit based on Haemonetics stock price during the 30 trading days prior to March 31, 2017. The number of Market Stock Units (and therefore the number of shares payable) will depend on the Companys stock price during such period. The Market Stock Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to three times the target amount in column 5. The Market Stock Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d).

By: Alexander Steffan For:  
Brian Concannon

08/05/2013

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**